Overexpression of Prothymosin Alpha Predicts Poor Disease Outcome in Head and Neck Cancer

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2011 May 17

PMID 21573209

Citations 20

Authors

Satyendra Chandra Tripathi

Ajay Matta

Jatinder Kaur

Jorg Grigull

Shyam Singh Chauhan

Alok Thakar

Nootan Kumar Shukla

Ritu Duggal

Ajoy Roy Choudhary

Siddhartha Dattagupta

Mehar Chand Sharma

Ranju Ralhan

K W Michael Siu

Affiliations

Soon will be listed here.

Abstract

Background: In our recent study, tissue proteomic analysis of oral pre-malignant lesions (OPLs) and normal oral mucosa led to the identification of a panel of biomarkers, including prothymosin alpha (PTMA), to distinguish OPLs from histologically normal oral tissues. This study aimed to determine the clinical significance of PTMA overexpression in oral squamous cell hyperplasia, dysplasia and head and neck squamous cell carcinoma (HNSCC).

Methodology: Immunohistochemistry of PTMA protein was performed in HNSCCs (n = 100), squamous cell hyperplasia (n = 116), dysplasia (n = 50) and histologically normal oral tissues (n = 100). Statistical analysis was carried out to determine the association of PTMA overexpression with clinicopathological parameters and disease prognosis over 7 years for HNSCC patients.

Results: Our immunohistochemical analysis demonstrated significant overexpression of nuclear PTMA in squamous cell hyperplasia (63.8%), dysplasia (50%) and HNSCC (61%) in comparison with oral normal mucosa (p(trend)<0.001). Chi-square analysis showed significant association of nuclear PTMA with advanced tumor stages (III+IV). Kaplan Meier survival analysis indicated reduced disease free survival (DFS) in HNSCC patients (p<0.001; median survival 11 months). Notably, Cox-multivariate analysis revealed nuclear PTMA as an independent predictor of poor prognosis of HNSCC patients (p<0.001, Hazard's ratio, HR = 5.2, 95% CI = 2.3-11.8) in comparison with the histological grade, T-stage, nodal status and tumor stage.

Conclusions: Nuclear PTMA may serve as prognostic marker in HNSCC to determine the subset of patients that are likely to show recurrence of the disease.

Citing Articles

HE2Gene: image-to-RNA translation via multi-task learning for spatial transcriptomics data.

Chen X, Lin J, Wang Y, Zhang W, Xie W, Zheng Z Bioinformatics. 2024; 40(6).

PMID: 38837395 PMC: 11164830. DOI: 10.1093/bioinformatics/btae343.

CD44-SNA1 integrated cytopathology for delineation of high grade dysplastic and neoplastic oral lesions.

Sunny S, D R R, Hariharan A, Mukhia N, Gurudath S, G K PLoS One. 2023; 18(9):e0291972.

PMID: 37747904 PMC: 10519609. DOI: 10.1371/journal.pone.0291972.

Identification of Potential Biomarkers Using Integrative Approach: A Case Study of ESCC.

Saikia M, Bhattacharyya D, Kalita J SN Comput Sci. 2022; 4(2):114.

PMID: 36573207 PMC: 9769493. DOI: 10.1007/s42979-022-01492-4.

First Evidence of the Expression and Localization of Prothymosin α in Human Testis and Its Involvement in Testicular Cancers.

Venditti M, Arcaniolo D, De Sio M, Minucci S Biomolecules. 2022; 12(9).

PMID: 36139050 PMC: 9496091. DOI: 10.3390/biom12091210.

Overexpression of prothymosin-α in glioma is associated with tumor aggressiveness and poor prognosis.

Kumar A, Kumar V, Arora M, Kumar M, Ammalli P, Thakur B Biosci Rep. 2022; 42(4).

PMID: 35297481 PMC: 9069441. DOI: 10.1042/BSR20212685.

References

Warnakulasuriya S . Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2008; 45(4-5):309-16. DOI: 10.1016/j.oraloncology.2008.06.002. View

Wu C, Shiau A, Lin C . Prothymosin alpha promotes cell proliferation in NIH3T3 cells. Life Sci. 1997; 61(21):2091-101. DOI: 10.1016/s0024-3205(97)00882-5. View

Shiwa M, Nishimura Y, Wakatabe R, Fukawa A, Arikuni H, Ota H . Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI ProteinChip platform. Biochem Biophys Res Commun. 2003; 309(1):18-25. DOI: 10.1016/s0006-291x(03)01520-1. View

Rodriguez P, Vinuela J, Alvarez-Fernandez L, Buceta M, Vidal A, Dominguez F . Overexpression of prothymosin alpha accelerates proliferation and retards differentiation in HL-60 cells. Biochem J. 1998; 331 ( Pt 3):753-61. PMC: 1219414. DOI: 10.1042/bj3310753. View

Orre R, Cotter 2nd M, Subramanian C, Robertson E . Prothymosin alpha functions as a cellular oncoprotein by inducing transformation of rodent fibroblasts in vitro. J Biol Chem. 2000; 276(3):1794-9. DOI: 10.1074/jbc.M008560200. View

Letsas K, Frangou-Lazaridis M . Surfing on prothymosin alpha proliferation and anti-apoptotic properties. Neoplasma. 2006; 53(2):92-6. View

Ralhan R, Desouza L, Matta A, Tripathi S, Ghanny S, Dattagupta S . iTRAQ-multidimensional liquid chromatography and tandem mass spectrometry-based identification of potential biomarkers of oral epithelial dysplasia and novel networks between inflammation and premalignancy. J Proteome Res. 2008; 8(1):300-9. DOI: 10.1021/pr800501j. View

Jiang X, Kim H, Shu H, Zhao Y, Zhang H, Kofron J . Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway. Science. 2003; 299(5604):223-6. DOI: 10.1126/science.1076807. View

Ralhan R, Desouza L, Matta A, Tripathi S, Ghanny S, Gupta S . Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry. Mol Cell Proteomics. 2008; 7(6):1162-73. PMC: 2424195. DOI: 10.1074/mcp.M700500-MCP200. View

10.

Maserejian N, Joshipura K, Rosner B, Giovannucci E, Zavras A . Prospective study of alcohol consumption and risk of oral premalignant lesions in men. Cancer Epidemiol Biomarkers Prev. 2006; 15(4):774-81. DOI: 10.1158/1055-9965.EPI-05-0842. View

11.

Matta A, Bahadur S, Duggal R, Gupta S, Ralhan R . Over-expression of 14-3-3zeta is an early event in oral cancer. BMC Cancer. 2007; 7:169. PMC: 2082039. DOI: 10.1186/1471-2407-7-169. View

12.

Hapke S, Kessler H, Luber B, Benge A, Hutzler P, Hofler H . Ovarian cancer cell proliferation and motility is induced by engagement of integrin alpha(v)beta3/Vitronectin interaction. Biol Chem. 2003; 384(7):1073-83. DOI: 10.1515/BC.2003.120. View

13.

Wang F, Arun P, Friedman J, Chen Z, Van Waes C . Current and potential inflammation targeted therapies in head and neck cancer. Curr Opin Pharmacol. 2009; 9(4):389-95. PMC: 2731001. DOI: 10.1016/j.coph.2009.06.005. View

14.

Sankaranarayanan R, Masuyer E, Swaminathan R, Ferlay J, Whelan S . Head and neck cancer: a global perspective on epidemiology and prognosis. Anticancer Res. 1999; 18(6B):4779-86. View

15.

Karetsou Z, Martic G, Tavoulari S, Christoforidis S, Wilm M, Gruss C . Prothymosin alpha associates with the oncoprotein SET and is involved in chromatin decondensation. FEBS Lett. 2004; 577(3):496-500. DOI: 10.1016/j.febslet.2004.09.091. View

16.

Ben-Yosef T, Yanuka O, Halle D, Benvenisty N . Involvement of Myc targets in c-myc and N-myc induced human tumors. Oncogene. 1998; 17(2):165-71. DOI: 10.1038/sj.onc.1201939. View

17.

Yang C, Murti A, Baker S, Frangou-Lazaridis M, Vartapetian A, Murti K . Interferon induces the interaction of prothymosin-alpha with STAT3 and results in the nuclear translocation of the complex. Exp Cell Res. 2004; 298(1):197-206. DOI: 10.1016/j.yexcr.2004.04.008. View

18.

Leys C, Nomura S, LaFleur B, Ferrone S, Kaminishi M, Montgomery E . Expression and prognostic significance of prothymosin-alpha and ERp57 in human gastric cancer. Surgery. 2006; 141(1):41-50. DOI: 10.1016/j.surg.2006.05.009. View

19.

Tzai T, Tsai Y, Shiau A, Wu C, Shieh G, Tsai H . Urine prothymosin-alpha as novel tumor marker for detection and follow-up of bladder cancer. Urology. 2006; 67(2):294-9. DOI: 10.1016/j.urology.2005.08.034. View

20.

Letsas K, Frangou-Lazaridis M, Skyrlas A, Tsatsoulis A, Malamou-Mitsi V . Transcription factor-mediated proliferation and apoptosis in benign and malignant thyroid lesions. Pathol Int. 2005; 55(11):694-702. DOI: 10.1111/j.1440-1827.2005.01899.x. View